CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: A multinational, multicohort European study

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3021990 41 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: A multinational, multicohort European study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL). Methods: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models. Results: We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36-52) and 37 years (IQR 31-44), respectively. Median observed pretreatment CD4 cell counts/mm3 were 203 (95% CI 100-290) in HIV-2+ patients and 223 (95% CI 100-353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12months were +105 (95% CI 77-134) in HIV-2+ patients and +202 (95% CI 199-205) in HIV-1+ patients, an observed difference of 97 cells/mm3 in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm3/year lower (95% CI 5-44; P=0.0127) in HIV-2+ patients compared with HIV-1+ patients. Conclusions: A poorer CD4 cell increase during first-line cART was observed in HIV-2+patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2.
Έτος δημοσίευσης:
2017
Συγγραφείς:
Wittkop, L.
Arsandaux, J.
Trevino, A.
van der Loeff, M.S.
Anderson, J.
van Sighem, A.
Böni, J.
Brun-Vezinet, F.
Soriano, V.
Boufassa, F.
Brockmeyer, N.
Calmy, A.
Dabis, F.
Jarrin, I.
Dorrucci, M.
Duque, V.
Fätkenheuer, G.
Zangerle, R.
Ferrer, E.
Porter, K.
Judd, A.
Sipsas, N.V.
Lambotte, O.
Shepherd, L.
Leport, C.
Morrison, C.
Mussini, C.
Obel, N.
Ruelle, J.
Schwarze-Zander, C.
Sonnerborg, A.
Teira, R.
Torti, C.
Valadas, E.
Colin, C.
Friis-Møller, N.
Costagliola, D.
Thiebaut, R.
Chene, G.
Matheron, S.
Touloumi, G.
Warszawski, J.
Meyer, L.
Krause, M.M.
Ghosn, J.
Reiss, P.
Wit, F.
Prins, M.
Bucher, H.
Gibb, D.
Del Amo, J.
Thorne, C.
Mocroft, A.
Kirk, O.
Stephan, C.
Pérez-Hoyos, S.
Hamouda, O.
Bartmeyer, B.
Chkhartishvili, N.
Noguera-Julian, A.
Antinori, A.
Monforte, A.
Prieto, L.
Conejo, P.R.
Soriano-Arandes, A.
Battegay, M.
Kouyos, R.
Tookey, P.
Casabona, J.
Mirò, J.M.
Castagna, A.
Konopnick, D.
Goetghebuer, T.
Sönnerborg, A.
Sabin, C.
Garrido, M.
Haerry, D.
Berenguer, J.
Bohlius, J.
Bouteloup, V.
Cozzi-Lepri, A.
Monforte, A.A.
Davies, M.-A.
Amo, J.
Dunn, D.
Egger, M.
Furrer, H.
Guiguet, M.
Grabar, S.
Leroy, V.
Lodi, S.
Monge, S.
Nakagawa, F.
Paredes, R.
Phillips, A.
Puoti, M.
Schomaker, M.
Smit, C.
Sterne, J.
van der Valk, M.
Wyss, N.
n behalf of the COHERE in EuroCoord
ACHIeV2e Study Group
Περιοδικό:
The Journal of antimicrobial chemotherapy
Εκδότης:
Oxford University Press
Τόμος:
72
Αριθμός / τεύχος:
10
Σελίδες:
2869-2878
Λέξεις-κλειδιά:
darunavir; lopinavir; ritonavir; RNA directed DNA polymerase inhibitor; anti human immunodeficiency virus agent; virus RNA, adult; antiretroviral therapy; Article; CD4 lymphocyte count; clinical assessment; cohort analysis; comparative study; controlled study; European; female; follow up; human; Human immunodeficiency virus 1; Human immunodeficiency virus 1 infection; Human immunodeficiency virus 2; Human immunodeficiency virus 2 infection; immune response; major clinical study; male; observational study; outcome assessment; treatment duration; treatment response; virus load; blood; CD4+ T lymphocyte; drug effect; Europe; Human immunodeficiency virus 1; Human immunodeficiency virus 2; Human immunodeficiency virus infection; immunology; international cooperation; middle aged; virology, Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Europe; Female; HIV Infections; HIV-1; HIV-2; Humans; Internationality; Male; Middle Aged; RNA, Viral; Viral Load
Επίσημο URL (Εκδότης):
DOI:
10.1093/jac/dkx210
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.